Mogamulizumab is a fully humanized, defucosylated anti-CCR4 antibody that was approved by FDA in 2018 for the treatment of relapsed/refractory cutaneous T-cell lymphoma. The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.